PGHH Q1FY27 Profit Declines 34% to ₹1262.7 Crore; Revenue Down 7%
Procter & Gamble Hygiene and Health Care Limited reported its Q1 FY27 results. Total income decreased to ₹891.46 crore from ₹937.03 crore YoY. Profit for the quarter fell 34% to ₹126.27 crore from ₹192.06 crore. EPS was ₹38.90.
The decrease in profit and revenue for the quarter, while significant, does not indicate a fundamental shift in the company's long-term prospects. The impact is considered medium as it affects short-term investor sentiment but may not drastically alter the company's overall valuation.
The company reported a significant decline in profit and a decrease in total income compared to the same quarter last year, indicating a negative financial performance trend for the period.
Procter & Gamble Hygiene and Health Care Limited (PGHH) announced its unaudited financial results for the quarter ended June 30, 2026. The company's total income from operations for the quarter stood at ₹891.46 crore, a decrease from ₹937.03 crore in the corresponding quarter of the previous year.
Total expenses for the quarter were ₹731.26 crore, compared to ₹680.02 crore in the same period last year. Consequently, the profit before tax for the quarter ended June 30, 2026, was ₹169.63 crore, a significant drop from ₹264.70 crore in the prior year's quarter.
After accounting for income tax expenses, the company reported a profit for the period of ₹126.27 crore (₹1,262.7 million), a decrease of approximately 34% from ₹192.06 crore (₹1,920.6 million) in the quarter ended June 30, 2025. Basic and diluted earnings per share (EPS) for the quarter were ₹38.90, down from ₹59.17 in the previous year.
The Board of Directors approved these unaudited financial results at their meeting held on July 29, 2026. The limited review report from the statutory auditors has also been furnished.
What to do with a filing like this
Procter & Gamble Hygiene and Health Care Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Procter & Gamble Hygiene and Health Care Limited. Read the original for the full detail.